Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Phase 1/2 Completed 41 enrolled New York Medical College

NaSingle-groupOpen-labelTreatment

Summary

The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).

Timeline

Start: 2013-03
Primary completion: 2021-08
Completion: 2022-09

Publications

Hochberg J, Oesterheld J, Gardenswartz A, Flower A, Klejmont L, Basso J, Shi Q, Harrison L, Borowitz MJ, Loken MR, Cairo MS. Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial. EClinicalMedicine. 2025 Apr 28;83:103211. doi: 10.1016/j.eclinm.2025.103211. eCollection 2025 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clofarabine	Other / unclassified	20 mg/m2	—
Subject	Clofarabine	Other / unclassified	30 mg/m2	—
Subject	Clofarabine	Other / unclassified	35 mg/m2	—
Subject	Clofarabine	Other / unclassified	40 mg/m2	—
Subject	Mitoxantrone	Small molecule	12 mg/m2	—

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Summary

Timeline

Publications

Drugs

Indications